A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H..

A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H.. is a phase 2 interventional study registered as NCT00923481 by National Cancer Institute (NCI), with 37 participants recorded, started 2009-04 and reaching its primary completion in 2009-04. Interventions recorded: Fostamatinib disodium. Conditions recorded: Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell.

Linked to the drug Fostamatinib because the registry names it among its interventions and Head and neck squamous cell carcinoma and Pheochromocytoma and paraganglioma among its conditions. Registry record only: no result has been read by an editor.